MOLN · Molecular Partners AG
$4.25
+0.04 (+0.95%)
At close · Aug 17
Market Cap
$159.42M
Shares
37.51M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.25
Open$4.25
Day$4.25–4.25
52W close$3.47–5.13
Avg vol 30d5K
Short int1K · 0.0% float · 1.8d
Short vol62%
Last earningsJan 10, 2024
DataJun 2021–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
+7%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
47%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+4%
trailing
6-month return
−6%
trailing
YTD return
−3%
this year
Relative strength
−18%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+25% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -49.3% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
5 holders — mid 3-yr range
Squeeze score
25
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
59%
annualized · 1-yr
Max drawdown
−28%
past year
ATR
3.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
+7%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
47%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+25% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.00% of float · ▼ -49.3% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
5 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $4 · 47%
Range high $5
vs 200-day avg +2%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MOLN
this stock
Molecular Partners AG
|
$159.42M | -2.5% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +19.3% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +13.7% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.4% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +17.5% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MOLN | +2.2% | +3.9% | -5.7% | +8.1% | -2.5% |
| SPY | -0.1% | +4.1% | +12.4% | +3.4% | +13.3% |
| vs SPY | +2.2% | -0.2% | -18.1% | +4.7% | -15.8% |